Floatz logo

Crizotinib

Castration-Resistant Prostate Carcinoma

Dana-Farber Cancer InstituteSmall moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

230 Active assets in the Castration-Resistant Prostate Carcinoma cohort.

Asset / SponsorPhaseRating
Darolutamide
Bayer
Phase 4BBB
Enzalutamide
Prostate Cancer Clinical Trials Consortium
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Ding-Wei Ye
Phase 4BBB
RADIUM RA-223
University of California, San Francisco
Phase 4BB
Bms-907351
Rana McKay, MD
Phase 3BB

View all 50 →

Same molecule, other indications

Crizotinib is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
75 / 100
View asset →
inflammatory myofibroblastic tumorDormant
BB
Indicative ·
69 / 100
View asset →
ALK-positive anaplastic large cell lymphomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →